Jump to content

PubMed RSS Feed - - Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies.


rss

Recommended Posts

Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies.

Br J Dermatol. 2011 Nov 2;

Authors: Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M,

Abstract
Background:  Erythema of rosacea is thought to result from abnormal cutaneous vasomotor activity. Brimonidine tartrate (BT) is a highly selective α(2) -adrenergic receptor agonist with vasoconstrictive activity. Objective:  To determine the optimal concentration and dose regimen of topical BT gel for the treatment of erythema of rosacea and to evaluate its efficacy and safety. Methods:  In Study A, 122 subjects were randomized to receive a single application of BT 0.07%, 0.18%, 0.5% and vehicle. In Study B (4-week treatment and 4-week follow-up), 269 subjects were randomized to receive BT 0.5% once-daily (QD), BT 0.18% QD, vehicle QD, BT 0.18% twice-daily (BID) or vehicle BID. Evaluations included Clinician's Erythema Assessment (CEA), Patient's Self Assessment (PSA), chromameter measurements and adverse events. Results:  Study A - A single application of topical BT gel reduced facial erythema in a dose-dependent fashion. Significant difference between BT 0.5% and vehicle in chromameter redness value was observed from 30 minutes to 12 hours after application. Study B - BT 0.5% QD had a statistically superior success profile (defined as 2-grade improvement on both CEA and PSA over 12 hours) compared to vehicle QD on Days 1, 15 and 29 (all P<.001). No tachyphylaxis, rebound of erythema or aggravation of other disease signs (telangiectasia, inflammatory lesions) was observed. All regimens were safe and well-tolerated with similarly low incidence of adverse events. Conclusions:  Once-daily BT gel 0.5% is well-tolerated and provides significantly greater efficacy than vehicle gel for the treatment of moderate to severe erythema of rosacea.

PMID: 22050040 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=22050040&dopt=Abstract = URL to article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Unfortunately, your content contains terms that we do not allow. Please edit your content to remove the highlighted words below.
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

Terms & Rules